19 November 2024
Published on the occasion of World Children’s Day 2024, this video provides an overview of The Nyumbani Children’s Home in Kenya, which supports babies and children with HIV. Nyumbani, meaning “home” in Kiswahili, has evolved from a hospice into a residence for approximately 100 orphans and vulnerable children. The video discusses advancements in paediatric HIV medicines and the upcoming rollout of paediatric ALD, a fixed-dose combination for children living with HIV. It highlights the impact of access to adapted paediatric formulations in LMICs and the efforts of MPP and its partners in these initiatives.
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada, the World Intellectual Property Organization (WIPO) and the Government of Flanders. MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC.